Welcome to our dedicated page for Dynavax Technolo news (Ticker: DVAX), a resource for investors and traders seeking the latest updates and insights on Dynavax Technolo stock.
Dynavax Technologies Corp. operated as a commercial-stage biopharmaceutical company developing and commercializing vaccines, with recurring announcements centered on its marketed products, pipeline and corporate status. The company commercialized HEPLISAV-B® vaccine, a hepatitis B vaccine approved in the U.S., European Union and United Kingdom for adults, and CpG 1018® adjuvant, which is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines.
Recurring updates include HEPLISAV-B revenue and financial results, share repurchase authorizations, investor conference presentations, licensing and collaboration activity, and clinical disclosures for vaccine candidates such as Z-1018 for shingles. Coverage also includes governance changes, material agreements, shareholder voting matters, capital-structure disclosures and public-company status updates.
Dynavax Technologies (DVAX) has implemented a -duration stockholder rights plan in response to Deep Track Capital's recent accumulation of 13.6% of company stock. The plan grants stockholders one preferred share purchase right per common share as of November 8, 2024. Rights become exercisable if any entity acquires 15% ownership (18% for passive institutional investors), allowing holders to purchase additional shares at $52.00. The plan aims to protect stockholder value and prevent control acquisition without appropriate premium. The Rights Plan will be submitted for stockholder vote at the 2025 Annual Meeting and will expire thereafter unless ratified, in which case it continues until October 28, 2025.
Dynavax Technologies (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on vaccine development, has announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day. Interested parties can access the webcast through the company's investor relations website, with a replay available for 30 days. Participants are advised to register and connect 10 minutes before the call.
Dynavax Technologies (Nasdaq: DVAX) reported strong Q2 2024 financial results, highlighting record HEPLISAV-B net product revenue of $70.2 million, a 24% year-over-year increase. The company reaffirmed its full-year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 million. Dynavax's total estimated market share in the U.S. increased to approximately 42%, with significant growth in retail pharmacy and IDN segments.
The company initiated dosing in a Phase 1/2 trial for its novel shingles vaccine program, with clinical data expected in 2H 2025. Dynavax also provided updates on its Tdap and plague vaccine programs. Financially, the company reported total revenues of $73.8 million, a 22% year-over-year increase, and net income of $11.4 million or $0.09 per share basic. Cash and marketable securities stood at $735.6 million as of June 30, 2024.
Dynavax Technologies (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on innovative vaccines, has announced it will report its second quarter 2024 financial results on Tuesday, August 6, 2024, after U.S. financial markets close. The company will host a conference call and live audio webcast on the same day at 4:30 p.m. ET/1:30 p.m. PT.
Investors can access the live audio webcast through the 'Events & Presentations' page on the company's website. A replay will be available for 30 days following the event. To participate in the call, attendees must register using the provided caller registration link. It is recommended that participants join the conference call or webcast approximately 10 minutes before the scheduled start time.
Dynavax Technologies (Nasdaq: DVAX) has initiated a Phase 1/2 clinical trial of its investigational shingles vaccine, Z-1018. The study will assess the vaccine’s safety, tolerability, and immunogenicity in approximately 440 healthy adults aged 50-69 years in Australia. Z-1018, which uses the CpG 1018 adjuvant, aims to provide improved tolerability and strong CD4+ T-cell responses compared to the market-leading Shingrix® vaccine. The trial will determine the optimal dose and schedule for future studies and validate a Patient Reported Outcome measurement tool for differentiating Z-1018 on tolerability. Top-line results are expected in the second half of 2025.
Dynavax Technologies (Nasdaq: DVAX), a biopharmaceutical company focused on innovative vaccines, will present at two investor conferences in June 2024. The company will participate in the William Blair 44th Annual Growth Stock Conference on June 4 at 1:20 PM CT and the Goldman Sachs 45th Annual Global Healthcare Conference on June 10 at 4:00 PM ET. Webcasts of these presentations will be accessible on the company's website.
Dynavax Technologies (Nasdaq: DVAX) announced that the U.S. FDA has issued a Complete Response Letter (CRL) regarding its supplemental Biologics License Application (sBLA) for a four-dose HEPLISAV-B vaccine regimen for adults on hemodialysis. The CRL cited insufficient data to fully evaluate the effectiveness and safety of the regimen, due to the destruction of data source documents and an inadequate sample size in the HBV-24 study. This decision does not impact the current approved indications for HEPLISAV-B in the U.S., EU, and Great Britain, nor the European Commission's approval of the four-dose regimen for hemodialysis patients. Dynavax plans to meet with the FDA to explore options for providing additional data.
Dynavax reported $48 million in HEPLISAV-B vaccine net product revenue, a 10% increase year-over-year in Q1 2024. The company reaffirmed its full-year revenue guidance and FDA clearance to initiate Phase 1/2 trial of Z-1018 shingles program. Dynavax continues to evaluate strategic growth opportunities while focusing on expanding its hepatitis B vaccine market share.
Summary not available.
Summary not available.